Revolution Medicines: Dominant Pancreatic Cancer Position, Expanding RAS Franchise, and 2026 Catalyst Funnel Support Buy Rating

Stifel Nicolaus analyst Laura Prendergast has maintained their bullish stance on RVMD stock, giving a Buy rating today.

Laura Prendergast has given his Buy rating due to a combination of factors pointing to a significantly stronger strategic and clinical position for Revolution Medicines than the market currently reflects. He highlights that the company has built a dominant franchise in pancreatic cancer, with multiple Phase 3 trials of daraxonrasib already underway and more late‑stage studies planned that together make competitive encroachment difficult. Early data combining zoldonrasib with standard chemotherapy in first‑line pancreatic cancer show a high response rate with an acceptable safety profile, and management’s comments suggest the regimen could be clinically competitive.

Moreover, Prendergast emphasizes that the opportunity in first‑line non‑small cell lung cancer, including a first‑mover study targeting the G12D subset, represents a sizable potential revenue stream that is not yet fully captured in consensus expectations. He also notes that colorectal cancer is emerging as another growth avenue, with 2026 data potentially enabling a pivotal program. The preclinical asset RM‑055, designed to address resistance mechanisms to RAS‑targeted therapies, further enhances the long‑term pipeline story, especially in light of weaker performance from a rival pan‑KRAS program, which underscores the value of RVMD’s pan‑RAS approach. Finally, a dense calendar of 2026 catalysts and ongoing M&A speculation—without any acquisition premium yet baked into his current target—support maintaining a positive stance on the stock.

According to TipRanks, Prendergast is a 4-star analyst with an average return of 16.7% and a 66.67% success rate. Prendergast covers the Healthcare sector, focusing on stocks such as Revolution Medicines, Cogent Biosciences, and Tango Therapeutics.